Ignite Creation Date:
2024-05-06 @ 3:24 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04623749
Status:
UNKNOWN
Last Update Posted:
2021-06-14
First Post:
2020-11-04
Brief Title:
Percutaneous Versus EUS FNAC in Pancreatic Masses
Sponsor:
Ola Kamal Mohammed Galal
Organization:
Assiut University
Study Overview
Official Title:
Percutaneous Versus Endoscopic Guided Fine Needle Aspiration Cytology in Diagnosis of Pancreatic Masses
Status:
UNKNOWN
Status Verified Date:
2021-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We aim to evaluate the role of Ultrasound-guided USG fine needle aspiration cytology FNAC in diagnosis of pancreatic masses compared to endoscopic ultrasound EUS guided fine needle aspiration cytology FNAC
Detailed Description:
Pancreatic cancer is the fourth leading cause of cancer-related mortality in the United States Over 45000 patients are diagnosed each year in the United States and the majority of these patients succumb to their disease Eighty percentages of patients are diagnosed with advanced unrespectable disease According to the latest statistics only 7 of patients survive 5 years after diagnosis While the 5-year survival rate improves to 25 in patients presenting with stage 1or localized disease only 9 of patients are identified at this early stage The majority of patients 53 presents with distant metastatic disease and have a 5-year survival of 2
Improving the prognosis of patients with pancreatic cancer is a challenge Overall pancreatic cancer has one of the worst prognoses among all cancers however the prognosis is better if cancer is detected at an early stage For example patients with pancreatic cancers 1 cm in size at the time of diagnosis have a 5-year survival rate of 804 Because such small cancers now account for 08 of all pancreatic cancer detection of more small cancers would contribute to improving mortality rates
The diagnostic approach to a possible pancreatic mass lesion relies first upon various non-invasive imaging modalities including computed tomography ultrasound and magnetic resonance imaging techniques Once a suspect lesion has been identified tissue acquisition for characterization of the lesion is often paramount in developing an individualized therapeutic approach Tools in addition to radiologic imaging currently employed in the initial evaluation of a patient with a pancreatic mass lesion include serum tumor markers endoscopic retrograde cholangiopancreatography Ultrasound-guided USG fine needle aspiration cytology FNAC and endoscopic ultrasound-guided fine needle aspiration EUS-FNA
Advancements in radiologic and endoscopic ultrasound EUS imaging have improved our ability to detect and stage pancreatic masses allowing for more selective surgical intervention for patients with resectable disease Owing to the low sensitivity of cross-sectional imaging to detect small tumors in the pancreas
Endoscopic ultrasound EUS in which the tip of the endoscope contains a high-frequency transducer provides high resolution images of the pancreas Indeed its high resolution in experienced hands enables detection of focal lesions as small as 2-5 mm
Ultrasound-guided USG fine needle aspiration cytology FNAC has emerged as a primary diagnostic modality in investigation in patients with pancreatic lesions This technique was introduced into clinical practice nearly 3 decades ago and has proved to be a simple cost-effective and minimally invasive technique that can yield material for tissue diagnosis
Improving the prognosis of patients with pancreatic cancer is a challenge Overall pancreatic cancer has one of the worst prognoses among all cancers however the prognosis is better if cancer is detected at an early stage For example patients with pancreatic cancers 1 cm in size at the time of diagnosis have a 5-year survival rate of 804 Because such small cancers now account for 08 of all pancreatic cancer detection of more small cancers would contribute to improving mortality rates
The diagnostic approach to a possible pancreatic mass lesion relies first upon various non-invasive imaging modalities including computed tomography ultrasound and magnetic resonance imaging techniques Once a suspect lesion has been identified tissue acquisition for characterization of the lesion is often paramount in developing an individualized therapeutic approach Tools in addition to radiologic imaging currently employed in the initial evaluation of a patient with a pancreatic mass lesion include serum tumor markers endoscopic retrograde cholangiopancreatography Ultrasound-guided USG fine needle aspiration cytology FNAC and endoscopic ultrasound-guided fine needle aspiration EUS-FNA
Advancements in radiologic and endoscopic ultrasound EUS imaging have improved our ability to detect and stage pancreatic masses allowing for more selective surgical intervention for patients with resectable disease Owing to the low sensitivity of cross-sectional imaging to detect small tumors in the pancreas
Endoscopic ultrasound EUS in which the tip of the endoscope contains a high-frequency transducer provides high resolution images of the pancreas Indeed its high resolution in experienced hands enables detection of focal lesions as small as 2-5 mm
Ultrasound-guided USG fine needle aspiration cytology FNAC has emerged as a primary diagnostic modality in investigation in patients with pancreatic lesions This technique was introduced into clinical practice nearly 3 decades ago and has proved to be a simple cost-effective and minimally invasive technique that can yield material for tissue diagnosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None